Pharmaceutical

PharmPix Corp. Joins Forces With Mark Cuban Cost Plus Drug Company to Revolutionize Pharmacy Benefits

Revolutionizing Pharmacy Benefits: PharmPix and Cost Plus Drugs Partner to Deliver Unprecedented Medication Cost Transparency and Affordability DALLAS, TEXAS /…

1 year ago

Phase 2 Study Initiated to Evaluate Jaguar Health’s Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies -…

1 year ago

Verisante Technology, Inc. Announces RTO Update:

RTO Partner SunRegen Healthcare AG Closes Private Placement for $2.1 Million VANCOUVER, BC / ACCESSWIRE / December 18, 2024 /…

1 year ago

Lexaria Forms New Scientific Advisory Board

North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18,…

1 year ago

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies…

1 year ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to…

1 year ago

Rafarma pharmaceutical updates

Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA)  Dear Rafarma shareholders, We apologize for the…

1 year ago

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec.…

1 year ago

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology…

1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -…

1 year ago